Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy for Alzheimer's disease.

Patrick L McGeer1, Edith McGeer

  • 1Kinsmen Laboratory of Neurological Research at the University of British Columbia, Vancouver, BC V6T 1Z3, Canada. mcgeerpl@interchange.ubc.ca

Science of Aging Knowledge Environment : SAGE KE
|July 10, 2004
PubMed
Summary

Alzheimer's disease (AD) research shows amyloid-beta (Abeta) vaccination clears plaques in mice but causes brain inflammation in humans. A dual approach stimulating microglial phagocytosis and anti-inflammatory activity may benefit AD patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Saliva Diagnosis as a Disease Predictor.

Journal of clinical medicine·2020
Same author

Application of multisegment injection on quantification of creatinine and standard addition analysis of urinary 5-hydroxyindoleacetic acid simultaneously with creatinine normalization.

Electrophoresis·2019
Same author

Conquering Alzheimer's Disease by Self Treatment.

Journal of Alzheimer's disease : JAD·2018
Same author

Alzheimer's Disease Can Be Spared by Nonsteroidal Anti-Inflammatory Drugs.

Journal of Alzheimer's disease : JAD·2017
Same author

Biological Imaging with Medium-Sensitive Bichromatic Flexible Fluorescent Dyes.

Angewandte Chemie (International ed. in English)·2017
Same author

Evidence that the Human Innate Immune Peptide LL-37 may be a Binding Partner of Amyloid-β and Inhibitor of Fibril Assembly.

Journal of Alzheimer's disease : JAD·2017

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Chronic neuroinflammation is a key driver in Alzheimer's disease (AD) progression.
  • Amyloid-beta (Abeta) protein deposits are a primary target in AD research.
  • Current Abeta vaccination strategies show promise in mouse models but pose risks in humans.

Purpose of the Study:

  • To explore a novel therapeutic strategy for Alzheimer's disease.
  • To investigate a dual-action approach for managing neuroinflammation and Abeta pathology.

Main Methods:

  • Review of existing research on Abeta vaccination in Alzheimer's disease models.
  • Analysis of the differential inflammatory responses between mouse models and human patients.
  • Hypothesizing a combined immunomodulatory strategy.

Related Experiment Videos

Main Results:

  • Abeta vaccination effectively clears amyloid plaques in transgenic mouse models of AD.
  • Human trials of Abeta vaccination have resulted in meningoencephalitis in some patients.
  • Higher baseline neuroinflammation in human AD patients likely contributes to adverse effects.

Conclusions:

  • Targeting amyloid-beta requires careful consideration of the host inflammatory environment.
  • A potential therapeutic strategy involves stimulating microglial phagocytosis while concurrently promoting anti-inflammatory activity.
  • This dual approach may offer a safer and more effective treatment for Alzheimer's disease.